Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
| ▸ | KLK1 | P06870 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21608346 | 0.88 | LMNA (0.39) | LMNAHTTTSHRSMN1; SMN2KDM4E | |
| SCHEMBL21608322 | 0.85 | LMNA (0.36) | LMNAHTTTSHRSMN1; SMN2KDM4E | |
| SCHEMBL21608334 | 0.81 | LMNA (0.35) | LMNAHTTTSHRSMN1; SMN2KDM4E | |
| SCHEMBL21608523 | 0.80 | RXFP1 (0.36) | LMNAHTTTSHRSMN1; SMN2KDM4E | |
| SCHEMBL21608265 | 0.79 | CYP17A1 (0.36) | LMNAHTTTSHRSMN1; SMN2KDM4E | |
| SCHEMBL21603424 | 0.78 | LMNA (0.48) | LMNAHTTTSHRSMN1; SMN2KDM4E | |
| SCHEMBL21608306 | 0.78 | HTR2A (0.33) | LMNAHTTTSHRSMN1; SMN2KDM4E | |
| SCHEMBL21608318 | 0.77 | RXFP1 (0.34) | LMNAHTTSMN1; SMN2KDM4EMAPT | |
| SCHEMBL21608283 | 0.77 | LMNA (0.34) | LMNAHTTTSHRSMN1; SMN2KDM4E | |
| SCHEMBL21608263 | 0.77 | DYRK1A (0.39) | SMN1; SMN2KDM4EMAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210277003-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-09 | — | — | US | disclosed |
| WO-2019243535-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277003-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | LMNA 848/4885HTT 33/4885TSHR 4632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.